Save for later

CSG 2: Prevention, targets & therapies for Type 1 diabetes

CSG 2 aims to further research into preventing and treating Type 1 diabetes. This CSG will cover the manipulation of the immune system for the prevention and treatment of Type 1 diabetes, alongside cell therapy and islet cell transplantation. 

The group will also cover therapeutic targets and the development and study of drug treatments and insulin therapy in people with Type 1 diabetes. 

Chair: Professor Colin Dayan, Cardiff University

Professor Colin Dayan has a long established interest in the underlying biology of Type 1 diabetes and is currently conducting early phase clinical trials in the development of Type 1 diabetes immunotherapy. 

Who's involved?

CSGs are bringing together researchers, healthcare professionals and people with diabetes to create a roadmap for new research.

  • Associate Professor Ramzi Ajjan, Associate Professor/Consultant in Diabetes and Endocrinology, University of Leeds
  • Dr James Cantley, Diabetes UK RD Lawrence Fellow, University of Oxford 
  • Dr Ivy Cheung, statistician, Swansea University
  • David Dupont, lay member 
  • Mirjam Eiswirth, lay member 
  • Dr Shareen Forbes, Reader Diabetes and Endocrinology and Honorary Consultant Diabetes and Endocrinology/Lead Diabetologist Islet Transplant Programme (Scotland)
  • Professor John Gregory, Professor in Paediatric Endocrinology & Honorary Consultant, Cardiff University
  • Elaine Hibbert-Jones, Dietician
  • Katherine Jones, Diabetes Research nurse 
  • Becki Millar, lay member 
  • Dr Parth Narendran, Reader in Diabetes Medicine/ Honorary Consultant Physician, University of Birmingham 
  • Dr Vinod Patel, Principal Clinical Teaching Fellow / Hon Consultant Physician, Diabetes & Endocrinology / Clinical Director for Diabetes, University of Warwick
Brand Icons/Telephone check - FontAwesome icons/tick icons/uk